(Q26743380)

English

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

0 references

5 references

23 March 2019

22 June 2019

17 September 2019

7 November 2019

28 October 2022

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis (English)

0 references

multiple drug resistance

0 references

0 references

pulmonary tuberculosis

5 references

23 March 2019

22 June 2019

17 September 2019

7 November 2019

28 October 2022

heterocyclic compound

1 reference

17 September 2019

1 reference

7 November 2019

carboxylic acid

1 reference

7 November 2019

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Akosua Adom Agyeman

1

0 references

Richard Ofori-Asenso

2

0 references

language of work or name

0 references

publication date

22 June 2016

5 references

23 March 2019

22 June 2019

17 September 2019

7 November 2019

28 October 2022

Annals of Clinical Microbiology and Antimicrobials

5 references

23 March 2019

22 June 2019

17 September 2019

7 November 2019

28 October 2022

15

0 references

1

0 references

41

0 references

copyright license

Creative Commons Attribution 4.0 International

5 references

Europe PubMed Central

23 March 2019

Europe PubMed Central

22 June 2019

Europe PubMed Central

17 September 2019

Europe PubMed Central

7 November 2019

Europe PubMed Central

28 October 2022

copyright status

0 references

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1186/s12941-016-0156-y

0 references

Extensively drug-resistant tuberculosis: epidemiology and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

7 April 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

7 April 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

7 April 2017

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Randomized clinical trials to identify optimal antibiotic treatment duration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

New treatment options for multidrug-resistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Linezolid in the treatment of multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Using existing systematic reviews in complex systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Linezolid for the treatment of multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 September 2017

Three-minute critical appraisal of a case series article

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

31 May 2018

Cost of multi drug resistance tuberculosis in Germany

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Linezolid for extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy.

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

On linezolid efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Linezolid in the treatment of MDR-TB: a retrospective clinical study

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Lessons from a randomised clinical trial for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2FS12941-016-0156-Y

21 January 2018

Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 November 2018

Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4917997

28 November 2018

Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linezolid in the treatment of extensively drug-resistant tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China

1 reference

https://pubmed.ncbi.nlm.nih.gov/27334498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12941-016-0156-Y

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12941-016-0156-y

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26743380&oldid=1947641523"